Cost of that treatment is a million dollars. It cures sickle cell anemia, but it's a million dollars. If we could get a generic drug, Biosimilar, that does the exact same thing for a fraction of the cost, we can make that treatment available in every state. Right now it is barely economic for the insurance companies because they think that maybe the treatment, the long term treatment of somebody with sickle cell anemia is going to cost more than that million dollars, but it's right on the borderline. (33:43–33:58)
CLAIM
Asserts that a biosimilar drug could make sickle cell anemia treatment more affordable and widely available.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
